Molecular Human Reproduction, Vol. 5, No. 7, 656-661,
July 1999
© 1999 European Society of Human Reproduction and Embryology
Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle
1 Department of Obstetrics and Gynecology, Faculty of Medicine, Osaka University, 2–2 Yamada-oka, Suita City, Osaka 565-0871, 2 Department of Obstetrics and Gynecology, Osaka Police Hospital, 10–31 Kitayama-cho, Tennouji-ku, Osaka 543-8502, and 3 Department of Gynecology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1–3–3 Nakamichi, Higashinari-ku, Osaka 537-0025, Japan.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Secretory leukocyte protease inhibitor (SLPI) is a potent inhibitor of human leukocyte elastase. SLPI transcripts in the cervical tissue were detected during the menstrual cycle by reverse transcription–polymerase chain reaction (RT–PCR). Western blot analysis revealed that the intensity of SLPI protein in cervical tissue in the ovulatory phase was stronger than in other phases. Immunohistochemistry using an anti-SLPI polyclonal antibody revealed positive staining in the epithelial cells of the endocervix. Western blot analysis also revealed that SLPI protein was present in the cervical mucus. Again the intensity of SLPI protein in the ovulatory phase was stronger than that in the follicular phase. The SLPI concentrations and SLPI/elastase ratios in the cervical mucus of women in the ovulatory phase were significantly higher than in the follicular and luteal phases. The SLPI and elastase concentrations in the cervical mucus were positively correlated. No significant difference was found in the SLPI serum concentrations of women during the menstrual cycle. These results suggest that production of SLPI from cervical epithelial cells during the ovulatory phase may be important for protection from the effects of elastase.
cervical mucus/ovulation/secretory leukocyte protease inhibitor (SLPI)
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
It is important for the investigation of infertility to evaluate cervical factor and sperm–cervical mucus interactions. Abnormalities of the cervix and its secretion are responsible for infertility in ~5–10% of infertile women (Moghissi, 1995
). Cervical mucus is a complex secretion produced constantly by the secretory cells of the endocervix. The cervix produces mucus at the rate of 20–60 mg/day in normal women of reproductive age. During the midcycle, the amount increases 10–20-fold and may reach up to 700 mg/day (Moghissi and Syner, 1976). Cyclic variations in the amount, physical properties, and chemical content of the cervical mucus constituents have been reported. From the termination of menstruation to the time of ovulation, viscosity and flow elasticity progressively decrease and spinbarkeit increases. After ovulation and during the luteal phase, spinbarkeit decreases and flow elasticity and viscosity markedly increase (Moghissi, 1995). Cervical mucus has bacteriostatic and bactericidal properties against certain strains of bacteria. Various bacteria are unable to migrate in a capillary tube filled with ovulatory cervical mucus. Bactericidal activity of the human cervical mucus is present during all phases of the menstrual cycle but is least pronounced at ovulation (Enhorning et al., 1970).
Pooled human cervical mucus contains ~1–3% protein in two basic forms, soluble proteins and mucin (Moghissi, 1995). The major components of soluble proteins are albumin and gamma globulin. Cyclic variations in the amounts of several proteins in cervical mucus have been described. In general, there appears to be a pre-ovulatory decrease and a post-ovulatory increase in the amounts of albumin, 
1-antitrypsin, and immunoglobulins (Ig) (Schumacher and Pearl 1968; Schumacher, 1970). Mucins comprise 45% of proteins in the cervical mucus. Mucin plays an important role in sperm transport. The secretion of cervical mucus is regulated by ovarian hormones. Oestrogen stimulates the production of copious amounts of watery mucus, whereas progesterone inhibits the secretory activity of cervical epithelial cells (Moghissi, 1995). The change of cervical mucus may also influence sperm penetrability, nutrition, and survival. Pre-ovulatory mucus is most receptive to sperm penetration (Moghissi et al., 1972).
Secretory leukocyte protease inhibitor (SLPI) is a potent inhibitor of human leukocyte elastase, human cathepsin G, and human trypsin (Thompson and Ohlsson, 1986). The concentrations of SLPI in biological samples have been monitored to correlate these concentrations with pathological conditions (Kida et al., 1992; Kouchi et al., 1993; Sluis et al., 1994). SLPI is found in various fluids, including parotid secretions (Thompson and Ohlsson, 1986), bronchial, nasal (Fryksmark et al., 1989), cervical mucus (Casslen et al., 1981; Helmig et al., 1995), and seminal plasma (Ohlsson et al., 1995; Moriyama et al., 1998). We have reported the beneficial effect of SLPI on sperm motility damaged by elastase. No study of the relationship between SLPI and elastase in cervical mucus during menstrual cycle has been reported. Evaluations of SLPI concentrations and elastase titres in the cervical mucus and SLPI gene transcript in the cervical tissue are necessary. In this study, SLPI protein was detected in the cervical mucus and cervical tissue by Western blot analysis. SLPI and elastase were quantified in cervical mucus from women with normal menstrual cycles by an enzyme-linked immunosorbent assay (ELISA). SLPI transcripts were also demonstrated in the cervical tissue by reverse transcription–polymerase chain reaction (RT–PCR) and SLPI producing cells by an immunohistochemical method.
|
Materials and methods |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Samples
A total of 11 non-pregnant women (aged 24–35 years) with normal ovulatory cycles confirmed by basal body temperature and vaginal sonography were recruited for this study, and informed consent was obtained. None of the subjects had a history of venereal infection, and women infected with bacteria or Chlamydia were excluded. Ovulation was confirmed by a urinary luteinizing hormone (LH) test, transvaginal sonography, mid-luteal phase progesterone and basal body temperature charts. Cervical secretion samples (n = 155) were collected with sterile Dacron swabs as previously described (Kanai et al., 1997
); the Dacron swab was used to aspirate 150 µl of cervical mucus. The samples were diluted with saline for 30 min at room temperature. Debris and cells were removed by centrifugation at 1000 g for 15 min, and the supernatants were stored at –20°C until titration to determine the SLPI and elastase concentrations. At the time of collection of cervical mucus, serum was also collected and stored at –80°C until the titration of SLPI. For use in a Western blot analysis, some of the cervical mucus samples in the follicular phase and the ovulatory phase were obtained by aspiration from the endocervix with a long tuberculin syringe. It was impossible to collect cervical mucus in the luteal phase by aspiration with a long tuberculin syringe. Surgical specimens of the cervix were obtained at a hysterectomy for uterine myoma with informed consent, and fresh frozen sections were prepared immediately.
Cell lines
The Hela cell lines were purchased from American Type Culture Collection (Rockville, MD, USA).
Reagents
Goat anti-SLPI polyclonal antibodies and recombinant SLPI (Escherichia coli expressed) were purchased from R & D Systems (Minneapolis, MN, USA). A control goat IgG for the control of a histochemical analysis was purchased from Zymed Laboratories (San Francisco, CA, USA).
RNA extraction
RNA was extracted from cervical tissue samples of 0.5 g wet weight and the Hela cell lines by acid guanidine thiocyanate– phenol–chloroform extraction according to a previously described method (Chomczynski and Sacchi, 1987). Briefly, cervical tissue samples were rapidly homogenized in 1 ml of denaturing solution (4 mol/l guanidinium thiocyanate, 25 mmol/l sodium citrate, 0.5% sarcosyl, 0.1 mol/l 2-mercaptoethanol) at room temperature. The viscous solution was then transferred to a 5 ml polypropylene tube. Sequentially, 100 µl of 2 mol/l of sodium acetate (pH 4.0), 1 ml of acid phenol (water-saturated), and 0.2 ml of chloroform and isoamyl alcohol mixture (49:1, vol:vol) were added to the homogenate, with mixing by inversion after the addition of each reagent. The mixture was then vigorously shaken and placed on ice for 15 min. Samples were centrifuged at 10 000 g, the aqueous phase containing the RNA was transferred to another set of polypropylene tubes and mixed with 1 volume of isopropanol. Precipitation of RNA was performed at –20°C for 30 min. Total RNA was then sedimented at 10 000 g for 10 min at 4 °C. The RNA pellets were pooled and dissolved in 0.3 ml of denaturing solution, and the RNA was re-precipitated with 0.3 ml isopropanol for 30 min at –20°C. The sedimented RNA was washed in 75% ethanol and air-dried. The dry RNA pellet was resuspended in 10 µl of diethylprocarbonate water, and the RNA concentration was assayed by measurement of the optical density at 260 nm.
RT–PCR amplification
RT–PCR was carried out using an RT–PCR high kit (Toyobo Co, Tokyo, Japan). The reaction was carried out in the presence of Maloney murine leukaemia virus reverse transcriptase (M-MLVRTase) and 1 µl RNA sample in a 5x RTase buffer, random primers, and dNTP mix for 40 min at 42°C. PCR amplification was performed, using an RT mixture (10 µl), with sequence-specific primers against human SLPI (5'-ACTCCTGCCTTCACCATGAA-3'/5'-CATTCGATCAACTGGCACTT-3'). PCR was carried out for 35 cycles using a thermal cycler (Perkin-Elmer/Cetus, Norwalk, CT, USA). Each cycle consisted of denaturation at 94°C (40 s), annealing at 52°C (40 s), and extension at 72°C (40 s). The amplification yielded a 570 bp DNA product according to the published sequence of the SLPI gene (Stetler et al., 1986). PCR products were digested by BamHI to confirm that they were exact SLPI gene transcripts. After digestion, the 570 bp DNA product was digested to 336 and 234 bp DNA. RT was performed with total RNA without reverse transcriptase (a mock RT sample) to detect possible contamination in RNA samples by genomic DNA. A 20 µl aliquot of a 50 µl PCR mixture was electrophoresed on a 4% agarose gel and stained in ethidium bromide, and amplified products were visualized by UV illumination. Molecular sizes were estimated using a 100 bp DNA ladder. All primers were obtained from Becks (Tokyo, Japan).
Tissue preparation for Western blot analysis
The homogenizing buffer for protein extraction from the cervical tissue consisted of 0.5 M Tris–HCl (pH 6.8), 10% sodium dodecyl sulphate (SDS), 6% ß-mercaptoethanol, and 1% Bromophenol Blue (BPB). The cervical tissues were homogenized in a 2 ml volume. Homogenates were centrifuged at 4°C for 30 min at 14 000 g to remove debris. Following protein determinations, the samples were divided into aliquots, and subjected to polyacrylamide gel electrophoresis (PAGE).
Protein assay
Protein concentrations were determined with Bio-Rad (Hercules, CA, USA) Protein Determination Reagent, according to the method of Bradford (Bradford, 1976).
Western blot analysis of cervical mucus and cervical tissue
To determine SLPI protein in the cervical mucus and the cervical tissue, Western blot analysis was carried out using an anti-human SLPI polyclonal antibody. Cervical mucus (10 µl) and ~10 µg of cervical tissue protein were electrophoresed on a 15% SDS–polyacrylamide gel and transferred onto nitrocellulose membranes (0.45 µm; Schleicher and Schuell, Dassel, Germany). The membrane was incubated with 5% dried milk protein followed by anti-human SLPI polyclonal antibody. The primary antibody was used at a final concentration of 1.0 µg/ml. The SLPI immunoreactivity was visualized using an enhanced chemiluminescence (ECL) Western blotting analysis system (Amersham, Aylesbury, UK).
Immunohistochemical staining of SLPI in the uterine cervix
To determine the localization of SLPI in the uterine cervix, we performed immunohistochemical staining using an avidin–biotin peroxidase complex method kit (OminiTags Universal Streptavidin/Biotin Affinity Immunostaining Systems, Lipshaw, Pittsburg, PA, USA). Fresh frozen sections of the cervix were bleached in 0.3% hydrogen peroxide to block endogenous peroxidase and covered with 2% goat IgG to minimize non-specific binding. The appropriately diluted goat polyclonal anti-SLPI antibody (R & D Systems, Minneapolis, MN, USA) or control goat IgG for the control was applied at room temperature and left for 1 h. After rinsing with phosphate-buffered saline solution, the sections were further incubated for 30 min with biotin-labelled goat anti-mouse immunoglobulin G, followed by the addition of avidin–peroxidase complex at 4°C. Peroxidase activity in the sections was visualized with 0.1% 3,3-diaminobenzidinine-tetrahydrochloride containing 0.02% hydrogen peroxide in 0.1 mol/l Tris buffer (pH 7.2). The slides were counterstained with Mayer's haematoxylin.
Determination of SLPI in the cervical mucus by ELISA
To determine concentrations of SLPI in the cervical mucus, ELISA kits utilizing a monoclonal antibody specific for SLPI (R & D Systems, Minneapolis, MN, USA) were used. The SLPI concentration detection limit of this kit was 62.5 pg/ml. No cross-reactivity with cytokines, growth factors, elastase, trypsin, and chymotrypsin could be found in this kit. The intra-assay variation of the SLPI kit was 4.2–8.0%, and its inter-assay variation was 4.9–8.0%.
Determination of elastase titre in the cervical mucus by ELISA
To measure the titres of elastase in the cervical mucus, ELISA kits specific for elastase (Merck, Darmstadt, Germany) were used. Cervical mucus titres of elastase which the kit detected were >1.0 µg/l. The intra-assay and inter-assay variation of the elastase kit were 2.7–5.2% and 4.9–9.5% respectively.
Statistical analysis
Statistical analyses of SLPI, elastase concentrations, and the SLPI/elastase ratio in cervical mucus were conducted using a non-parametric test; P < 0.05 was considered to be statistically significant. The correlation between SLPI and elastase in cervical mucus was analysed by simple linear regression.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
RT–PCR was performed to determine the expression of the SLPI gene in the cervical tissue during the menstrual cycle. Figure 1
shows that SLPI transcripts were present in the cervical tissue during the menstrual cycle. As shown in Figure 2, the Western blot analysis detected SLPI protein in the cervical tissue as a 12 kDa band. The intensity of SLPI in the cervical tissue in the ovulatory phase was stronger than that in both the follicular and luteal phases. To identify the origin of this large amount of SLPI, we performed immunohistochemical staining of sections of the uterine cervix in the ovulatory phase, using an anti-SLPI polyclonal antibody. The cytoplasm of columnar epithelial cells in the endocervical glands, the subepithelial layers, and cervical mucus were intensely stained (Figure 3). To examine SLPI protein in the cervical mucus, we performed a Western Blot analysis. As shown in Figure 4, SLPI protein was detected as a 12 kDa band in the cervical mucus. The slightly lower molecular weight band seen in Figures 2 and 4 is thought to be a degradation product of SLPI. The intensity of SLPI protein in the ovulatory phase was stronger than that in the follicular phase. We determined the SLPI concentrations in the cervical mucus with a specific ELISA for SLPI. Figure 5 shows the SLPI concentrations in the cervical mucus of women during the menstrual cycle. The SLPI titres, elastase concentrations and SLPI/elastase ratio in the cervical mucus of each phase during the menstrual cycle were calculated by the average of those of each phase. The SLPI titres of cervical mucus in the follicular phase were in the range 7–667 ng/ml (median: 188 ng/ml) and those in the luteal phase in the range 14–520 ng/ml (median: 110 ng/ml), while those in the ovulatory phase were in the range 352–1040 ng/ml (median: 880 ng/ml). There is a significant difference between SLPI concentrations between the three phases (P < 0.0001). The elastase concentrations of cervical mucus in the follicular phase, in the ovulatory phase, and in the luteal phase were in the range 80–740 ng/ml (median: 130 ng/ml), from 170–1100 ng/ml (median: 310 ng/ml), and from 90–690 ng/ml (median: 300 ng/ml) respectively. No significant difference of elastase titres in the cervical mucus among in the three phases (P = 0.09) was observed. As shown in Figure 6, the SLPI/elastase ratio in the cervical mucus in the ovulatory phase was in the range from 0.079–0.462 (median: 0.149), while that in the follicular phase was in the range 0.005–0.279 (median: 0.055) and that in the luteal phase was in the range 0.006–0.230 (median: 0.036). The difference in the SLPI/elastase ratios of these three phases was significant (P < 0.001). We also examined the SLPI concentrations in the serum of the subjects. As shown in Table I, there was no significant difference in the SLPI serum concentrations during the menstrual cycle. To examine the correlation between SLPI and elastase concentrations in cervical mucus, a simple linear analysis was performed. The SLPI and elastase concentrations in the cervical mucus were positively correlated (y = 4.4x + 2220, r = 0.47, P < 0.0001).
|
|
|
|
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
In the present study, it was found that the SLPI gene is expressed during the menstrual cycle. No significant difference in SLPI gene expression was detected during the menstrual cycle by RT–PCR. However, there was a difference between the SLPI protein concentrations in the cervical tissue during the menstrual cycle. Western blot analysis revealed that the intensity of SLPI in the cervical tissue in the ovulatory phase was stronger than that in both the follicular and luteal phases. SLPI gene 5' flanking region has a TATA box and multiple potential nuclear activator protein-1 (AP-1) binding sites, which are capable of mediating a specific response to induction by phorbol esters. However the mechanisms controlling SLPI gene expression in vivo are unknown (Abe et al., 1991
). An immunohistochemical analysis using anti-SLPI polyclonal antibody showed that the columnar epithelial cells of the endocervical glands were intensely stained, indicating that these epithelial cells were the main source of SLPI in the cervical mucus. The results presented here of an immunohistochemical analysis are consistent with previous findings (Casslen et al., 1981).
The cervical mucus contains various kinds of enzymes, e.g. amylase, alkaline phosphatase, esterase, aminopeptidase, lactate dehydrogenase, and peroxidase. These enzymes show a marked pre-ovulatory decrease and post-ovulatory rise in response to progesterone in the luteal phase. It has been suggested that assays of some of the enzymes that exhibit a pre-ovulatory decline and post-ovulatory rise may be used to predict or detect ovulation (Moghissi, 1995). The change of SLPI concentrations in the cervical mucus of women during the menstrual cycle was observed in the present study. The mean SLPI titres of women in the ovulatory phase were higher than those of women in both the follicular phase and the luteal phase. However, there is no difference in the serum SLPI of the women during the menstrual cycle. These results indicate that the change in SLPI concentrations in cervical mucus is a localized reaction in the menstrual cycle. The secretion of cervical mucus is regulated by ovarian hormones. Oestrogen stimulates the production of copious amounts of watery mucus, whereas progesterone inhibits the secretory activity of cervical epithelial cells. SLPI production by the cervical tissue might be regulated by ovarian hormones. It was also reported that antileukoprotease concentrations in luteal phase cervical mucus were higher than those of the follicular and ovulatory phases (Casslen et al., 1981), in contrast to the results of this study. Casslen et al. reported that the latter part of the menstrual cycle is a period when numerous leukocytes are found in the uterus, a situation which presumably presents a significant task for inhibitors like SLPI. The discrepancy might be due to the different methods used to obtain cervical mucus and the different methods used to determine the protein concentrations. Further investigations are necessary to explain the discrepancy in results.
Cervical mucus has bacteriostatic and bacteriocidal properties. Elastase is a protease which is produced by leukocytes in the cervix (Moghissi, 1995). Cervical mucus and semen contain large amounts of elastase (Wolff and Anderson, 1988; Shimoya et al., 1993). However, no significant difference of elastase titres in the cervical mucus during the menstrual cycle was observed here. SLPI is an inhibitor of proteases such as leukocyte elastase (Ohlsson et al., 1995). In the present study, the mean SLPI titre and SLPI/elastase ratio of the women in the ovulatory phase were higher than those of the women in the follicular or luteal phases. The up-regulation of SLPI plays a defensive role in the epithelial surface of inflammatory lung diseases (Abbinante et al., 1993). SLPI might protect the cervical epithelium from the leukocyte protease of cervical mucus and semen.
The sperm–cervical mucus interaction is an important factor for fertilization. Cyclic alterations in the concentrations of cervical mucus may also influence sperm penetrability, nutrition, and survival. Pre-ovulatory mucus is most receptive to sperm penetration (Moghissi and Syner, 1976). It is usually inhibited within 1–2 days after ovulation but may persist to a lesser degree for a longer period (Moghissi, 1995). It has previously been demonstrated that SLPI recovered sperm motility reduced by elastase which is contained in the seminal plasma (Moriyama et al., 1998). In human cervical mucus, motile spermatozoa have been found 2–8 days after coitus (Moghissi, 1995). Because the cervical mucus in the ovulatory phase contains high amounts of SLPI, this molecule might have an important effect on the sperm penetrability of human cervical mucus. Further investigations are necessary to examine the relationship between SLPI concentrations and cervical factors in infertility.
|
Acknowledgments |
|---|
This work was supported in part by Grants-in-Aid for Scientific research (Nos. 20151061, 30203897, 50294062, 70283786, 80301266 and 90093478) from the Ministry of Education, Science, and Culture of Japan (Tokyo, Japan).
|
Notes |
|---|
4 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Faculty of Medicine, Osaka University, 2–2 Yamada-oka, Suita City, Osaka 565-0871, Japan. e-mail: shimoya{at}gyne.med.osaka-u.ac.jp
|
References |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Abbinante, N.J., Simpson, L.G. and Leikauf, G.D. (1993) Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am. J. Physiol., 265, L286–292.
Abe, T., Kobayashi, N., Yoshimura, K. et al. (1991) Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J. Clin. Invest., 87, 2207–2215.
Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248–254.[ISI][Medline]
Casslen, B., Rosengren, M. and Ohlsson, K. (1981) Localization and quantitation of a low molecular weight proteases inhibitor, antileukoprotease in the human uterus. Hoppe-Seyler's Z. Phusiol. Chem., 362, 953–961.
Chomczynski, P. and Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidium thiocyanate–phenol–chloroform extraction. Ann. Biochem., 162, 156.
Enhorning, G., Huldt, L. and Melen, B. (1970) Ability of cervical mucus to act as a barrier against bacteria. Am. J. Obstet. Gynecol., 108, 532–537.[ISI][Medline]
Fryksmark, U., Jannert, M., Ohlsson, K. et al. (1989) Secretory leukocyte protease inhibitor in normal, allergic and virus induced nasal secretions. Rhinology, 27, 97–103.[Medline]
Helmig, R., Uldbjerg, N. and Ohlsson, K. (1995) Secretory leukocyte protease inhibitor in the cervical mucus and in the fetal membranes. Eur. J. Obstet. Gynecol. Reprod. Biol., 59, 95–101.[ISI][Medline]
Kanai, T., Fukuda-Miki, M., Shimoya, K. et al. (1997) Increased interleukin-1 and interleukin-1 receptor antagonist levels in cervical mucus in the ovulatory phase in comparison with the follicular phase. Gynecol. Obstet. Invest., 43, 166–170.[ISI][Medline]
Kida, K., Mizuuchi, T., Takeyama, K. et al. (1992) Serum secretory leukoprotease inhibitor levels to diagnose pneumonia in the elderly. Am. Rev. Respir. Dis., 146, 1426–1429.[ISI][Medline]
Kouchi, I., Yasuoka, S., Ueda, Y. et al. (1993) Analysis of secretory leukocyte protease inhibitor (SLPI) in bronchial secretions from patients with hypersecretory respiratory diseases. Tokushima J. Exp. Med., 40, 95–107.[Medline]
Moghissi, K.S. (1995) Cervical factor in infertility. In Wallach, E.E. and Zacur, H.A. (eds), Reproductive Medicine and Surgery. Mosby Book Co, Chicago, USA, pp. 376–397.
Moghissi, K.S. and Syner, F.N. (1976) Cyclic changes in the amount of sialic acid of cervical mucus. Int. J. Fertil., 21, 246–250.
Moghissi, K.S., Syner, F.N. and Evans, T.N. (1972) A composite picture of the menstrual cycle. Am. J. Obstet. Gynecol., 114, 405–418.[ISI][Medline]
Moriyama, A., Shimoya, K., Kawamoto, A. et al. (1998) Secretory leukocyte protease inhibitor (SLPI) levels in seminal plasma: SLPI restores sperm motility reduced by elastase. Mol. Hum. Reprod., 4, 946–950.
Ohlsson, K., Bjartell, A. and Lilja, H. (1995) Secretory leukocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J. Androl., 16, 64–74.
Schumacher, G.F. (1970) Biochemistry of cervical mucus. Fertil. Steril., 21, 697–705.[ISI][Medline]
Schumacher, G.F. and Pearl, M.J. (1968) Alpha1-antitrypsin in cervical mucus. Fertil. Steril., 19, 91–99.[ISI][Medline]
Shimoya, K, Matsuzaki, N., Tsutsui, T. et al. (1993) Detection of interleukin-8 (IL-8) in seminal plasma and elevated IL-8 in seminal plasma of infertile patients with leukospermia. Fertil. Steril., 59, 885–888.[ISI][Medline]
Sluis, K.B., Darlow, B.A., Vissers, M.C. et al. (1994) Proteinase-antiproteinase balance in tracheal aspirates from neonates. Eur. Respir. J., 7, 251–259.[Abstract]
Stetler, G., Brewer, M.T. and Thompson, R.C. (1986) Isolation and sequence of a human gene coding a potent inhibitor of leukocyte preteases. Nucleic Acids Res., 14, 7883–7896.
Thompson, R.C. and Ohlsson, K. (1986) Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl Acad. Sci. USA, 83, 6692–6696.
Wolff, H. and Anderson, D.J. (1988) Evaluation of granulocyte elastase as a seminal plasma marker for leukocytospermia. Fertil. Steril., 50, 129–132.[ISI][Medline]
Submitted on November 26, 1998; accepted on April 9, 1999.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Andersson, D. Minjarez, N. P. Yost, and R. A. Word Estrogen and Progesterone Metabolism in the Cervix during Pregnancy and Parturition J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2366 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W Horne, S. J Stock, and A. E King Innate immunity and disorders of the female reproductive tract Reproduction, June 1, 2008; 135(6): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Klein, K. R. Jonscher, M. J. Heerwagen, R. S. Gibbs, and J. L. McManaman Shotgun Proteomic Analysis of Vaginal Fluid From Women in Late Pregnancy Reproductive Sciences, March 1, 2008; 15(3): 263 - 273. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Ming, P. Xiaoling, L. Yan, W. Lili, W. Qi, Y. Xiyong, W. Boyao, and H. Ning Purification of antimicrobial factors from human cervical mucus Hum. Reprod., July 1, 2007; 22(7): 1810 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Andersch-Bjorkman, K. A. Thomsson, J. M. Holmen Larsson, E. Ekerhovd, and G. C. Hansson Large Scale Identification of Proteins, Mucins, and Their O-Glycosylation in the Endocervical Mucus during the Menstrual Cycle Mol. Cell. Proteomics, April 1, 2007; 6(4): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ota, K. Shimoya, Q. Zhang, A. Moriyama, R. Chin, K. Tenma, T. Kimura, M. Koyama, C. Azuma, and Y. Murata The expression of secretory leukocyte protease inhibitor (SLPI) in the Fallopian tube: SLPI protects the acrosome reaction of sperm from inhibitory effects of elastase Hum. Reprod., October 1, 2002; 17(10): 2517 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, K. Shimoya, A. Moriyama, K. Yamanaka, A. Nakajima, T. Nobunaga, M. Koyama, C. Azuma, and Y. Murata Production of secretory leukocyte protease inhibitor by human amniotic membranes and regulation of its concentration in amniotic fluid Mol. Hum. Reprod., June 1, 2001; 7(6): 573 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. SUZUMORI, M. SATO, K. IKUTA, and K. SUZUMORI Secretory Leukocyte Protease Inhibitor in Ovarian Endometriomas Following GnRH Agonist Therapy Obstet. Gynecol., April 1, 2001; 97(4): 561 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shimoya, A. Moriyama, I. Ogata, T. Nobunaga, M. Koyama, C. Azuma, and Y. Murata Increased concentrations of secretory leukocyte protease inhibitor in peritoneal fluid of women with endometriosis Mol. Hum. Reprod., September 1, 2000; 6(9): 829 - 834. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||